Suppr超能文献

新型 N-(4-氰基-1,3-恶唑-5-基)磺酰胺衍生物的合成、表征及对 NCI-60 癌细胞系活性的体外筛选。

Synthesis, characterization of novel N-(4-cyano-1,3-oxazol-5-yl)sulfonamide derivatives and in vitro screening their activity against NCI-60 cancer cell lines.

机构信息

Department of Chemistry of bioactive nitrogen-containing heterocyclic bases, V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, 1, Academician Kukhar str, 02094, Kyiv, Ukraine.

Department of Biomedical Research, V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, 1, Academician Kukhar str, 02094, Kyiv, Ukraine.

出版信息

ChemMedChem. 2024 Mar 1;19(5):e202300527. doi: 10.1002/cmdc.202300527. Epub 2024 Feb 12.

Abstract

A novel series of N-(4-cyano-1,3-oxazol-5-yl)sulfonamides have been synthesized and characterized by IR, H NMR, C NMR spectroscopy, elemental analysis and chromato-mass-spectrometry. The anticancer activities of all newly synthesized compounds were evaluated via a single high-dose assay (10 μM) against 60 cancer cell lines by the National Cancer Institute (USA) according to its screening protocol. Among them, compounds 2 and 10 exhibited the highest activity against the 60 cancer cell lines panel in the one-dose assay. Compounds 2 and 10 showed inhibitory activity within the GI parameter and in five dose analyses. However, their cytostatic activity was only observed against some cancer cell lines, and cytotoxic concentration was outside the maximum used, i. e., >100 μM. The COMPARE analysis showed that the average graphs of the tested compounds have a moderate positive correlation with compounds with the L-cysteine analog and vinblastine (GI ) as well as paclitaxel (TGI), which target microtubules. Therefore, disruption of microtubule formation may be one of the mechanisms of the anticancer activity of the tested compounds, especially since among tubulin inhibitors with antitumor activity, compounds with an oxazole motif are widely represented. Therefore, N-(4-cyano-1,3-oxazol-5-yl)sulfonamides may be promising for further functionalization to obtain more active compounds.

摘要

一种新型的 N-(4-氰基-1,3-恶唑-5-基)磺酰胺类化合物已经通过红外光谱、核磁共振氢谱、核磁共振碳谱、元素分析和色谱-质谱等方法进行了合成和表征。根据美国国立癌症研究所(NCI)的筛选方案,采用单次高剂量测定法(10 μM)对 60 种癌细胞系进行了所有新合成化合物的抗癌活性评估。其中,化合物 2 和 10 在单次剂量测定中对 60 种癌细胞系的活性最高。化合物 2 和 10 在 GI 参数和 5 个剂量分析中表现出抑制活性。然而,它们的细胞增殖活性仅在一些癌细胞系中观察到,细胞毒性浓度超过了最大使用浓度,即>100 μM。COMPARE 分析表明,所测试化合物的平均图谱与 L-半胱氨酸类似物和长春碱(GI)以及紫杉醇(TGI)具有中度正相关,后者是靶向微管的化合物。因此,破坏微管形成可能是测试化合物抗癌活性的机制之一,特别是因为在具有抗肿瘤活性的微管蛋白抑制剂中,具有恶唑基序的化合物广泛存在。因此,N-(4-氰基-1,3-恶唑-5-基)磺酰胺类化合物可能具有进一步功能化以获得更活性化合物的潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验